Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01676935 · ClinicalTrials.gov registry record · Phase 2
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Terminated
- Registry status
- Phase 2
- Development phase
- 349
- Enrollment target
NCT01676935: Clinical Trial Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
NCT01676935 is a Phase 2 study that was terminated before completion, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 349 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (162% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01676935, a Phase 2 study, was terminated before completion, sponsored by AbbVie (prior sponsor, Abbott).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 349 participants
- Enrollment target
Study Summary
This is a long term extension study to evaluate safety and tolerability of subjects who complete study M10-985 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
Primary Outcome
Monitor each subject for clinical and laboratory evidence of adverse events on a routine basis throughout the study
Interventions
- DRUG ABT-126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Why NCT01676935 stopped before completion
NCT01676935 is an interventional study that assigns participants to a tested intervention. The registered 349 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (162% higher).
The record links to 0 conditions, and to 1 intervention - of which ABT-126 is the first listed.
NCT01676935 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01676935 about?
NCT01676935 is a clinical study titled "This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease". This is a long term extension study to evaluate safety and tolerability of subjects who complete study M10-985 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
What is the current status of trial NCT01676935?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 349 participants. The study started on 2012-08. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01676935?
The interventions under investigation include: ABT-126 (DRUG).
Who is sponsoring clinical trial NCT01676935?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01676935's enrollment target sits among peer trials
349 136th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia